ZA201907819B - Antibodies recognizing tau - Google Patents

Antibodies recognizing tau

Info

Publication number
ZA201907819B
ZA201907819B ZA2019/07819A ZA201907819A ZA201907819B ZA 201907819 B ZA201907819 B ZA 201907819B ZA 2019/07819 A ZA2019/07819 A ZA 2019/07819A ZA 201907819 A ZA201907819 A ZA 201907819A ZA 201907819 B ZA201907819 B ZA 201907819B
Authority
ZA
South Africa
Prior art keywords
antibodies recognizing
tau
recognizing tau
antibodies
specifically bind
Prior art date
Application number
ZA2019/07819A
Other languages
English (en)
Inventor
Philip Payne
Robin Barbour
Svetlana Alexander
Mark E Renz
Shuning Gai
Philip James Dolan
Tarlochan S Nijjar
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of ZA201907819B publication Critical patent/ZA201907819B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
ZA2019/07819A 2017-05-02 2019-11-26 Antibodies recognizing tau ZA201907819B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500427P 2017-05-02 2017-05-02
US201762580408P 2017-11-01 2017-11-01
PCT/US2018/030739 WO2018204546A2 (en) 2017-05-02 2018-05-02 Antibodies recognizing tau

Publications (1)

Publication Number Publication Date
ZA201907819B true ZA201907819B (en) 2024-07-31

Family

ID=64016242

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07819A ZA201907819B (en) 2017-05-02 2019-11-26 Antibodies recognizing tau

Country Status (17)

Country Link
US (2) US11958896B2 (enExample)
EP (1) EP3619233A4 (enExample)
JP (2) JP7442790B2 (enExample)
KR (1) KR102784294B1 (enExample)
CN (1) CN110881274B (enExample)
AU (1) AU2018263935B2 (enExample)
BR (1) BR112019022906A2 (enExample)
CA (1) CA3061516A1 (enExample)
CO (1) CO2019013265A2 (enExample)
CU (1) CU24636B1 (enExample)
IL (1) IL270375B2 (enExample)
MX (1) MX2019013045A (enExample)
MY (1) MY206891A (enExample)
PE (1) PE20200695A1 (enExample)
SG (1) SG11201910066QA (enExample)
WO (1) WO2018204546A2 (enExample)
ZA (1) ZA201907819B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
BR112018072394A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
EP3688155B1 (en) 2017-09-28 2023-01-04 Immpact-Bio Ltd. A universal platform for preparing an inhibitory chimeric antigen receptor (icar)
TWI853617B (zh) * 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN113891746B (zh) * 2019-03-26 2025-05-06 詹森药业有限公司 焦谷氨酸淀粉样蛋白-β的抗体及其用途
CN115867304A (zh) 2020-05-19 2023-03-28 欧萨尔普罗席纳有限公司 用于治疗阿兹海默症的多抗原决定基疫苗
AU2021321549A1 (en) 2020-08-07 2023-03-09 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
EP4208176A4 (en) * 2020-09-04 2025-06-25 Gavish-Galilee Bio Applications Ltd. Constructs of the bicistronic inhibiting chimeric antigen receptor (ICAR)/activating chimeric antigen receptor (ACAR) for use in cancer therapies
KR20230146056A (ko) * 2021-02-14 2023-10-18 프로테나 바이오사이언시즈 리미티드 타우 인식 항체를 사용하는 방법
CN116047081B (zh) * 2023-01-10 2024-02-13 北京新源长青生物科技有限公司 检测Aβ40、Aβ42的试剂盒与方法

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
JP2879975B2 (ja) 1992-12-14 1999-04-05 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管関連タンパク質タウに対するモノクローナル抗体、これらの抗体を分泌するハイブリドーマ、これらのモノクローナル抗体による抗原認識及びこれらの応用
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CN100489892C (zh) 1999-02-05 2009-05-20 三星电子株式会社 恢复描述图像的纹理特征的图像纹理描述符的方法及装置
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
AU2003257850A1 (en) 2002-08-14 2004-03-03 Mitsubishi Kagaku Iatron, Inc. ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
AU2003302689B2 (en) 2002-11-29 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
US7847146B2 (en) 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20050132424A1 (en) 2003-10-21 2005-06-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Dutch
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
WO2006074071A1 (en) 2004-12-30 2006-07-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Framework residue substituted humanized col-1 antibodies and their use
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
AU2007261584A1 (en) 2006-06-16 2007-12-27 Envivo Pharmaceutical Inc. Transgenic flies expressing tau and amyloid precursor fragment
AU2007262666B2 (en) 2006-06-22 2013-09-12 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008022153A2 (en) 2006-08-14 2008-02-21 The Regents Of The University Of California Inhibitors of pde4 and methods of use
CA2671457C (en) 2006-12-01 2017-09-26 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
HUE034512T2 (en) 2007-01-05 2018-02-28 Univ Zuerich A method for providing disease-specific binding molecules and targets
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
MX2011001911A (es) 2008-08-18 2011-07-04 Pfizer Anticuerpos para ccr2.
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
SG176060A1 (en) 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
US8778343B2 (en) 2009-08-28 2014-07-15 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
US20120288507A1 (en) * 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
CN102711812B (zh) 2010-01-08 2014-07-16 国立大学法人京都大学 Tau蛋白病治疗用疫苗
MX2012009215A (es) 2010-02-23 2012-11-23 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
EP2560681A4 (en) 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
US20140050733A1 (en) 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
EP2701743A4 (en) * 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6281163B2 (ja) 2011-08-22 2018-02-21 エメルゲント バイオソリューションズ カナダ クロストリジウム・ディフィシレ抗体
AU2012311234B2 (en) * 2011-09-19 2017-09-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN108034005B (zh) 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
WO2013059786A1 (en) 2011-10-21 2013-04-25 The Ohio State University Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
PL2831113T3 (pl) * 2012-03-28 2018-08-31 Sanofi Przeciwciała przeciwko ligandom receptora bradykininy B1
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
WO2013158696A1 (en) 2012-04-18 2013-10-24 E. I. Du Pont De Nemours And Company Multilayered sheet
DE102012211455A1 (de) 2012-07-02 2014-01-02 Wobben Properties Gmbh Handhabungsvorrichtung zum Handhaben einer Rotorblattform zum Fertigen eines Rotorblattes einer Windenergieanlage
MX359555B (es) 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
EP3685854A1 (en) 2012-08-16 2020-07-29 Ipierian, Inc. Methods of treating a tauopathy
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2887933A1 (en) 2012-10-12 2014-04-17 Arizona Board Of Agents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
SG11201504822VA (en) 2012-12-21 2015-07-30 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9364191B2 (en) 2013-02-11 2016-06-14 University Of Rochester Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
CU24446B1 (es) * 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
WO2014152773A1 (en) 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
US10325457B2 (en) 2013-08-29 2019-06-18 Sony Corporation Wristband-type information processing device, information processing system, and information processing method
BR112016010454A2 (pt) 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
US20160333063A1 (en) 2013-12-13 2016-11-17 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
PT3083689T (pt) 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
CA2952745A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CN107428820B (zh) 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA2977648C (en) 2015-02-24 2024-01-02 Rpeptide, Llc Anti-tau antibodies
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
WO2016201434A2 (en) 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
JP6937289B2 (ja) 2015-07-06 2021-09-22 ユーシービー バイオファルマ エスアールエル Ｔａｕ結合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017013599A1 (en) 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
CN108738323B (zh) 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
BR112018072394A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
US10947302B2 (en) 2016-11-04 2021-03-16 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
MY198942A (en) 2016-12-07 2023-10-03 Genentech Inc Anti-tau antibodies and methods of use
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
WO2018156250A1 (en) 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
TWI848907B (zh) 2017-03-28 2024-07-21 美商建南德克公司 治療神經退化性疾病之方法
EP3601335A1 (en) 2017-03-28 2020-02-05 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
EA202090063A1 (ru) 2017-06-16 2020-04-03 Бристоль-Мейерз Сквибб Компани Композиции и способы для лечения таупатий
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
CA3084098A1 (en) 2017-12-04 2019-06-13 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TW202003036A (zh) 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
MX2020009991A (es) 2018-03-28 2020-10-14 Axon Neuroscience Se Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2020096608A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
CN119409813A (zh) 2018-11-08 2025-02-11 普罗塞纳生物科学有限公司 识别tau的抗体
WO2020106598A1 (en) 2018-11-19 2020-05-28 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
SG11202106717PA (en) 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
JP7595061B2 (ja) 2019-07-15 2024-12-05 アデル，インコーポレーテッド 抗タウ抗体およびその使用

Also Published As

Publication number Publication date
JP2023113836A (ja) 2023-08-16
IL270375A (en) 2019-12-31
PE20200695A1 (es) 2020-06-16
AU2018263935B2 (en) 2024-09-26
IL270375B2 (en) 2024-12-01
US11958896B2 (en) 2024-04-16
AU2018263935A1 (en) 2019-12-19
JP7587304B2 (ja) 2024-11-20
CU20190087A7 (es) 2020-10-20
IL270375B1 (en) 2024-08-01
SG11201910066QA (en) 2019-11-28
CU24636B1 (es) 2022-12-12
EP3619233A2 (en) 2020-03-11
KR102784294B1 (ko) 2025-03-19
BR112019022906A2 (pt) 2020-05-26
MY206891A (en) 2025-01-13
CA3061516A1 (en) 2018-11-08
WO2018204546A3 (en) 2018-12-13
CO2019013265A2 (es) 2020-01-17
CN110881274B (zh) 2024-11-15
US12479910B2 (en) 2025-11-25
MX2019013045A (es) 2020-02-12
CN110881274A (zh) 2020-03-13
EP3619233A4 (en) 2021-03-03
JP2020520231A (ja) 2020-07-09
KR20200030029A (ko) 2020-03-19
JP7442790B2 (ja) 2024-03-05
WO2018204546A2 (en) 2018-11-08
US20240309078A1 (en) 2024-09-19
US20220089702A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
PH12018502054A1 (en) Antibodies recognizing tau
ZA201907819B (en) Antibodies recognizing tau
MY197413A (en) Antibodies recognizing tau
PH12021551048A1 (en) Antibodies recognizing tau
ZA202205817B (en) Antibodies recognizing tau
IL279321A (en) Anti-SIRPalpha antibody
IL277072A (en) Anti-claudin antibodies 18.2
SG11202106214YA (en) Novel anti-ccr8 antibody
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
IL280013A (en) Anti-IL36R antibodies
MX2020010040A (es) Anticuerpos que se unen a tau y usos de los mismos.
PH12017502180A1 (en) Tau-binding antibodies
AU2018448903A8 (en) Antibodies recognizing tau
GB201817172D0 (en) Antibody
PH12017502207A1 (en) Tau-binding antibodies
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
ZA202101177B (en) Anti-btla antibody
WO2018046997A3 (en) SYNTHETIC ANTIBODIES AGAINST VEGF AND USES THEREOF
GB201811368D0 (en) Antibody
MX2021010517A (es) Anticuerpos que reconocen tau.
HK40103775A (zh) 抗hla-dq2.5 抗体
WO2016135462A8 (en) Treatment
SG11202105718TA (en) Modified antibodies
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody